Literature DB >> 4397511

Exercise tolerance in patients with angina pectoris. Daily variation and effects of erythrityl tetranitrate, propranolol and alprenolol.

G R Dagenais, B Pitt, R S Ross.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4397511     DOI: 10.1016/0002-9149(71)90028-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  8 in total

1.  THE USE OF NON-INVASIVE TECHNIQUES IN MANAGEMENT OF PATIENTS WITH ANGINA PECTORIS ON ORAL PROPRANOLOL.

Authors:  William H. Frishman; Charles Smithen; Paul Kligfield; Thomas Killip
Journal:  Cardiovasc Dis       Date:  1974

2.  Reproducibility of exercise tests in patients with symptomatic ischaemic heart disease.

Authors:  J Fabián; I Stolz; M Janota; J Rohác
Journal:  Br Heart J       Date:  1975-08

3.  Antianginal efficacy of exercise training: a comparison with beta blockade.

Authors:  I C Todd; D Ballantyne
Journal:  Br Heart J       Date:  1990-07

4.  Effects of single doses of alprenolol and two cardioselective beta-blockers (H 87-07 and H 93-26) on exercise-induced angina pectoris.

Authors:  L Adolfsson; N H Areskog; C Furberg; G Johnsson
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

5.  Exercise tolerance in patients with angina pectoris after pentaerythritol trinitrate and alprenolol studied by two different methods.

Authors:  L G Ekelund; A Melcher; L Orö
Journal:  Eur J Clin Pharmacol       Date:  1975-06-13       Impact factor: 2.953

6.  Beta-adrenergic blockade in stress protection. Limited effect of metoprolol in psychological stress reaction.

Authors:  E Heidbreder; G Pagel; A Röckel; A Heidland
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

Review 7.  Effect of a bradycardic agent on the isolated blood-perfused canine heart.

Authors:  J D Schipke; Y Harasawa; S Sugiura; J Alexander; D Burkhoff
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

8.  Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial.

Authors:  Andrew J Morrow; Thomas J Ford; Kenneth Mangion; Tushar Kotecha; Roby Rakhit; Gavin Galasko; Stephen Hoole; Anthony Davenport; Rajesh Kharbanda; Vanessa M Ferreira; Mayooran Shanmuganathan; Amedeo Chiribiri; Divaka Perera; Haseeb Rahman; Jayanth R Arnold; John P Greenwood; Michael Fisher; Dirk Husmeier; Nicholas A Hill; Xiaoyu Luo; Nicola Williams; Laura Miller; Jill Dempster; Peter W Macfarlane; Paul Welsh; Naveed Sattar; Andrew Whittaker; Alex Mc Connachie; Sandosh Padmanabhan; Colin Berry
Journal:  Am Heart J       Date:  2020-07-17       Impact factor: 4.749

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.